Less than one in 10 people eligible to benefit from weight-loss injections like Wegovy have access to them, warns the World Health Organization as it publishes its initial guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer availability to this class of drugs.
Per forecasts, over two billion could be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a chronic disease that can be managed with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major obstacles to universal availability to the injections that can aid individuals in losing considerable body mass, explains the organization.
Weight-Loss Drug Scarcity
Despite the present most favorable scenario, the supply of such drugs could only cover around 100 million people – less than 10% of those who need them, as stated by the WHO.
The guideline calls on countries and companies to expand availability, by approaches like patent sharing.
The intellectual property rights on a key compound – the main component of a leading brand – is scheduled to end in several nations in 2026.
How Obesity Injections Function
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people consume fewer calories.
People commonly begin shedding pounds after several weeks of commencing the regular doses.
Evidence points to people may regain a significant portion after a year of halting the medication, because their typical food cravings return.
Being overweight or obese elevates your chance for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, as per the WHO.
